Tous Actualités
Suivre
Abonner AstraZeneca GmbH

AstraZeneca GmbH

Summary of Key 'Arimidex' (Anastrozole) Data From the 27th Annual San Antonio Breast Cancer Conference

San Antonio, Texas (ots/PRNewswire)

- New Trial Results Offer More Choice for More Women With Breast
Cancer
The ATAC ('Arimidex', Tamoxifen, Alone or in Combination)
Completed Treatment Analysis(1),(2): Presented by Professor Anthony
Howell and simultaneously published via fast-track peer-review in The
Lancet
The latest data from the ATAC Trial reveal that anastrozole is the
first drug in 30 years to be proven to be more effective than
tamoxifen in preventing the return of the disease, in postmenopausal
women with hormone-sensitive, early breast cancer. As a result, these
compelling data are expected to change current clinical practice.
Specifically, the results showed that 5 years of adjuvant anastrozole
therapy provides the following benefits, over and above those offered
by tamoxifen:
  • a 26% further reduction in the risk of recurrence (HR =0.74; p= <0.002)
  • a 53% further reduction in the risk of contralateral breast cancer (HR = 0.47; p = 0.001)
  • a 16% further reduction in the risk of distant recurrence (HR = 0.84; p= 0.06)(i)
For further information, please go to www.ATAC-news.com
Combined analysis of the ABCSG 8 Trial and the German ARNO 95
Trial(3): Presented by Professor Raimund Jakesz
The ABCSG and ARNO trials were designed to assess, in patients who
had already started a course of adjuvant treatment with tamoxifen,
whether changing therapy to anastrozole after 2 years is more
effective than continuing treatment with tamoxifen.
The results from the combined analysis of these trials have shown
that, by changing their therapy to anastrozole after 2 years of
tamoxifen women have a 40% lower risk of their cancer returning than
if they remain on tamoxifen treatment.
Commenting on these results, Professor Jakesz, of the Vienna
Medical School, Austria, said: "What we have seen here is that women
who change their therapy to anastrozole have a significantly lower
risk of their cancer returning than if they continue to take
tamoxifen. This is great news for the thousands of breast cancer
patients who have already started their adjuvant therapy with
tamoxifen, as it means that they can also benefit from the efficacy
and tolerability advantages that anastrozole offers over tamoxifen.
In his presentation at the conference Professor Jakesz concluded
that in order to lower the risk of recurrence, postmenopausal women
who are currently on adjuvant tamoxifen should be switched to
anastrozole after 2 years of treatment.
For further information, please go to
www.astrazenecapressoffice.com
Additional data suggest benefits for even more women
A further set of data(4) was presented for the first time this
week in San Antonio, which gave an early indication of the potential
of using anastrozole in younger women. By using anastrozole in
conjunction with another hormonal treatment 'Zoladex' (goserelin),
which acts by temporarily inducing the menopause, women appear to
benefit from the combined efficacy of the two drugs. Although using
the two drugs in this way has so far only been tested in a small
number of patients, the results from the trial suggest that goserelin
plus anastrozole may be an effective therapy for younger women with
advanced-stage breast cancer. This is particularly important as it
increases the range of treatment options, other than chemotherapy,
available for these women
Anastrozole and goserelin were both developed by AstraZeneca, a
company that is leading the way in producing innovative new treatment
options for breast cancer. Commenting on the data presented this
week, Bernie Tyrrell, Vice President of Oncology for AstraZeneca
said: "The San Antonio conference this year has seen the presentation
of an array of important and, in some cases, practice-changing new
data for AstraZeneca breast cancer treatments. These data move us
even closer to our goal of providing a full range of effective and
well-tolerated therapies, that can be used to treat women of any age,
and at any stage of the disease, providing more choices for more
women."
References
1. Howell A, on behalf of the ATAC Trialists' Group. The ATAC
('Arimidex', Tamoxifen, Alone or in Combination) trial in
postmenopausal women with early breast cancer - updated efficacy
results based on a median follow-up of 5 years. Abstract No. 1, San
Antonio Breast Cancer Symposium 2004.
2. The ATAC Trialists' Group. Results Of The ATAC ('Arimidex',
Tamoxifen, Alone Or In Combination) Trial After Completion Of 5
Years' Adjuvant Treatment For Breast Cancer. Available on line at
www.thelancet.com
3. Jakesz R, et al. Benefits of switching postmenopausal women
with hormone-sensitive early breast cancer to anastrozole after 2
years adjuvant tamoxifen: combined results from the 3,123 women
enrolled in the ABCSG Trial 8 and ARNO 95 Trial. Abstract No. 2, San
Antonio Breast Cancer Symposium 2004.
4. Carlson R et al, Goserelin plus anastrozole for the treatment
of premenopausal women with hormone receptor-positive, metastatic
breast cancer. Abstract no 6052 San Antonio Breast Cancer Symposium
2004.
Further information
(i) In the trial population as a whole (the intent to treat, ITT
population), the hazard ratio (HR) for distant recurrence was 0.86, p
= 0.04 - i.e. the value has reached statistical significance in
favour of 'Arimidex'. In the hormone-sensitive population (84% of the
total population), patients have a better prognosis and therefore too
few events have so far occurred to show significance (p=0.06). As
expected though, the HR for distant recurrence is actually more
favourable in hormone-sensitive patients (0.84) and this difference
is fully expected to become significant with time.
AstraZeneca continues its tradition of research excellence and
innovation in oncology that led to the development of its current
anti-cancer therapies including ARIMIDEX(TM) (anastrozole),
CASODEX(TM) (bicalutamide), FASLODEX(TM) (fulvestrant), NOLVADEX(TM)
(tamoxifen), ZOLADEX(TM) (goserelin), TOMUDEX(TM) (raltitrexed) and
IRESSA(TM) (gefitinib) as well as a range of novel targeted products
such as anti-proliferatives, anti-angiogenics, vascular targeting and
anti-invasive agents. AstraZeneca is also harnessing rational drug
design technologies to develop new compounds that offer advantages
over current cytotoxic and hormonal treatment options. The company
has over 20 different anti-cancer projects in research and
development.
Since AstraZeneca released its first anti-cancer drug, 'Nolvadex'
(tamoxifen), more than 25 years ago, investment in research has led
to the discovery of new anti-cancer agents and other innovative
therapeutic strategies which give AstraZeneca an extensive portfolio
of developmental agents to complement the established product range.
AstraZeneca's product range for breast cancer include the following:
  • 1973: Tamoxifen (NOLVADEX(TM)): a well-tolerated, oral anti-oestrogen. Now the most widely prescribed agent for the treatment of all stages of breast cancer worldwide.
  • 1990: Goserelin (ZOLADEX(TM)): a well-tolerated and widely-prescribed LHRH analogue, administered by sub-cutaneous injection every 28 days, which reduces sex hormone production. Goserelin is now used in the treatment of early and advanced breast cancer in pre-menopausal women with hormone-sensitive disease.
  • 1995: Anastrozole (ARIMIDEX(TM)): the first of a new class of drugs - selective 'aromatase inhibitors' - now widely used in the treatment of early and advanced breast cancer in post-menopausal women with hormone sensitive disease. Anastrozole is approved world-wide for postmenopausal women with advanced disease and as an adjuvant treatment for postmenopausal women with hormone receptor-positive early breast cancer in over 79 countries including the US, UK, Germany, Italy, Spain.
  • 2002: Fulvestrant (FASLODEX(TM)): a new type of breast cancer therapy (an oestrogen receptor antagonist without known agonist effects). 'Faslodex' is now approved in the European Union for the treatment of postmenopausal women with receptor-positive locally advanced or metastatic breast cancer, for disease relapse or progression on or after therapy with an anti-oestrogen such as tamoxifen. 'Faslodex' has been launched in the USA since May 2002 and more recently received regulatory approval throughout the 25 members countries in the European Union in March 2004.
AstraZeneca is a major international healthcare business engaged
in the research, development, manufacture and marketing of
prescription pharmaceuticals and the supply of healthcare services.
It is one of the world's leading pharmaceutical companies with
healthcare sales of over $18.8 billion and leading positions in sales
of gastrointestinal, oncology, cardiovascular, neuroscience and
respiratory products. AstraZeneca is listed in the Dow Jones
Sustainability Index (Global) as well as the FTSE4Good Index.
For further information, including webcasts of the data
presentations referred to above, please visit
www.astrazenecapressoffice.com
WEBCASTS OF KEY DATA PRESENTATIONS: www.astrazenecapressoffice.com

Contact:

Contact: Alison Wright, Global PR Manager, Oncology, AstraZeneca,
Tel: +44(0)1625-230-076 Mobile: +44(0)7879-487-331 Email:
Alison.K.Wright@astrazeneca.com

Plus de actualités: AstraZeneca GmbH
Plus de actualités: AstraZeneca GmbH
  • 10.12.2004 – 12:13

    More Choice for More Women

    San Antonio, Texas (ots/PRNewswire) - - 'The Latest Hormonal Treatment Options in the Breast Cancer Continuum' - An AstraZeneca Sponsored Webcast From the 2004 San Antonio Breast Cancer Symposium This webcast will announce key new data for 'FASLODEX' and 'ARIMIDEX' that is being presented at the 27th San Antonio Breast Cancer Symposium (SABCS), 8 - 11 December. The webcast explores the latest developments in the treatment of postmenopausal women with early ...

  • 16.11.2004 – 00:04

    New ASCO Recommendation for Postmenopausal Women With Early Breast Cancer

    London, November 15 (ots/PRNewswire) - - Optimal Adjuvant Therapy Should Now Include an AI Such as 'Arimidex' (anastrozole) in Order to Reduce the Risk of Tumour Recurrence Today, the American Society of Clinical Oncology (ASCO) Technology Assessment Panel announced a fundamental change to its internationally recognised guidance on the use of ...